Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG immunization in Alzheimer's disease
NCT05004688Phase 2Completed
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bcg vaccine in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI). Started Mar 2022; status: completed.
02
Drugs
bcg vaccine
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05004688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004688.